Alcohol use and cardiometabolic risk in the UK Biobank: a Mendelian randomization study

Joanna Lankester⁽¹⁾, Daniela Zanetti⁽¹⁾, Erik Ingelsson^(1,2), Themistocles L. Assimes^(1,3)

(1) Department of Medicine (Division of Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA.

(2) GlaxoSmithKline, Inc., Brentford, England, UK.

(3) VA Palo Alto Health Care System, Palo Alto, CA.

Abstract

Observational studies suggest alcohol use promotes the development of some adverse cardiometabolic traits but protects against others including outcomes related to coronary artery disease. We used Mendelian randomization to explore causal relationships between the degree of alcohol consumption and several cardiometabolic traits in the UK Biobank. We found carriers of the *ADH1B* Arg47His variant (rs1229984) reported a 26% lower amount of alcohol consumption compared to non-carriers. In our one-sample, two-stage least squares analyses of the UK Biobank using rs1229984 as an instrument, one additional drink/day was associated with statistically significant elevated level of systolic blood pressure (3.0 mmHg), body mass index (0.87 kg/m²), waist circumference (1.3 cm), body fat percentage (1.7%), low-density lipoprotein levels in blood (0.16 mmol/L), and the risk of myocardial infarction (OR=1.50), stroke (OR=1.52), any cardiovascular disease (OR=1.43), and all-cause mortality (OR=1.41). Conversely, increasing use of alcohol was associated with reduced levels of triglycerides (-0.059 mmol/L) and HbA1C (-0.42 mmol/mol) in the blood, the latter possibly a consequence of a statistically elevated mean corpuscular volume among *ADH1B* Arg47His carriers. Stratifications by sex and smoking revealed a pattern of more harm of alcohol use among men compared to women, but no consistent difference by smoking status. Men had an increased risk of heart failure (OR = 1.76), atrial fibrillation (OR = 1.35), and type 2 diabetes (OR = 1.31) per additional drink/day. Using summary statistics from external datasets in 2-sample analyses for replication, we found causal associations between alcohol and obesity, stroke, ischemic stroke, and type 2 diabetes. Our results are consistent with an overall harmful effect of alcohol on cardiometabolic health at all levels of use and suggest that even moderate alcohol use should not be promoted as a part of a healthy diet and lifestyle.

Introduction

The relationship between alcohol and cardiovascular disease is important to understand given the high prevalence of alcohol consumption [1, 2]. In decades of epidemiological work, alcohol consumption has shown an inverse or J-shape association with multiple traits related to cardiometabolic health including Type 2 diabetes [3, 4], non-fatal and fatal coronary heart disease [5-7], ischemic stroke [8-10], atrial-fibrillation [11], and congestive heart failure [12].

One interpretation of these relationships has been that moderate drinking is beneficial to cardiometabolic health. A problem with this interpretation is that the relationship is inconsistent with that observed for some known risk factors; for example, alcohol has been directly associated with outcomes such as hypertension irrespective of the degree of intake [13]. A long-standing hypothesis to reconcile these observations stipulates that the negative effects on blood pressure are modest and are surpassed by the positive effects on HDL levels [14, 15] that are either directly affected by alcohol and/or a consequence of an improvement in insulin sensitivity [16]. However, this hypothesis has been challenged in the last decade by multiple randomized control trials of HDL-raising drugs, as well as Mendelian randomization studies that have failed

to demonstrate the benefits on risk of cardiovascular disease (CVD) of pharmacologically or genetically raised HDL [17-19].

The extent to which observational studies can shed light on the relationship between alcohol and CVD is questionable due to confounding and reverse causality [20]. Alcohol use is related to cultural, socioeconomic, and lifestyle factors which cannot be fully accounted for in observational analyses. Furthermore, several studies have suggested substantial differences in the effects of alcohol on cardiometabolic traits between men and women [3, 4, 11, 12, 16, 21]. Mendelian randomization (MR) facilitates a comparison of groups of subjects that consume more vs. less alcohol that is free of confounding, allowing us to better understand the causal effect of consumption. In this study, we determine the causal relationship between alcohol and cardiovascular risk factors and disease in the UK Biobank by performing an instrumental variable analysis using a genetic variant in a gene (*ADH1B*) that is known to be responsible for the metabolism of alcohol and associated with the amount of alcohol consumed. We attempt to validate findings using summary statistics from external consortial studies for related phenotypes. Within the UK Biobank, we also take advantage of the large numbers to explore strength of associations stratified by sex and smoking status.

Methods

Study cohort

The UK Biobank is a prospective study of over 500,000 participants recruited in 2006–2010 [22]. Data collected from the participants included questionnaires, physical measures, sample assays, genotyping, and ongoing longitudinal hospital records. Participants were enrolled at age 40-69. This research has been conducted using the UK Biobank Resource under Application Number 13721. The Research Ethics Committee reference for UK Biobank is 16/NW/0274. The Stanford IRB reviewed the protocol and determined the research did not include human subjects as defined in 45 CFR 46, nor 21 CFR 56.

Outcomes and quantitative traits

We extracted systolic and diastolic blood pressure, BMI, waist circumference, and body fat percentage from survey data which included physical measurement at the baseline clinic visit. We obtained lipids, blood count variables, and HbA1C from the biomarkers data. We extracted primary and secondary diagnosis disease outcomes from hospital data for myocardial infarction, stroke (hemorrhagic, ischemic, and any stroke), heart failure, atrial fibrillation, and a composite outcome of all cardiovascular events combined, as well as death from each of these disease outcomes according to the relevant ICD codes (S1.1). We derived type 2 diabetes status from a combination of diabetes-related questions and self-reported medications (S1.2).

Main exposure and covariates

Our main exposure variable of interest was self-reported alcohol use by number of drinks per week or month and type of drink obtained from the survey data. Use of all types of alcohol was aggregated into total grams of alcohol intake per year [23], which was then transformed into equivalent daily glasses of wine (0, >0-1, >1-2, >2-3, and >3) to facilitate interpretability. Covariates also from survey data included sex, age, region of recruitment, socioeconomic status, ethnicity, smoking status, blood pressure medications, cholesterol-lowering medications, insulin and other diabetes drugs, and fasting status (for biomarkers) (S2).

We used Arg47His (rs1229984) in *ADH1B* as our genetic instrument for alcohol use. This variant is arguably the strongest and most established genetic predictor of self-reported alcohol use in European populations with a frequency of about 0.5% (Northern Europe) to 4% (Southern Europe) [24, 25]. The variant was directly genotyped using the UK Biobank array and thus no imputation of this variant was necessary.

Statistical analysis

We characterized the observational relationship between alcohol use and continuous variable risk factors using linear regression for quantitative traits, logistic regression for type 2 diabetes, and Cox proportional hazards regression for cardiovascular events or death. The reference group for all observational analyses was current non-drinkers. For our Cox analyses, we defined the start of follow up as time of enrollment into the UK Biobank study and excluded those with a cardiovascular event prior to the questionnaire to minimize survivor bias. We created two models for each outcome in our observational analysis, one model minimally adjusted for typical epidemiologic covariates (sex, age, region of recruitment, socioeconomic status, ethnicity, and smoking status; for biomarker outcomes, fasting status was also included) and one model additionally adjusted for heart disease risk factors as well as medications that affect those risk factors (BMI and waist circumference, in all models other than those for anthropometric measures; SBP and DBP, in all models other than those for blood pressure; HbA1C and diabetic medications, in models other than for type 2 diabetes; LDL, HDL, and triglycerides, in all models other than those for lipids; and lipid-lowering, or anti-hypertensive medications).

We included all non-related individuals of European descent (for sample independence and to avoid population stratification) in the UK Biobank for our MR analyses. We grouped heterozygous and homozygous carriers (dominant model). We quantified the strength of the instrument variable using ANOVA and tested the relationship between the instrument variable and alcohol consumption using linear regression. We performed a one-sample MR using the two-stage least squares method with individual level UK Biobank data to estimate the causal effect on traits of consuming one additional drink per day on average. Given possible differences in drinking patterns by sex and smoking status, we also conducted stratified analyses in male, female, current smoker, and never smoker subgroups. We used the Breslow-Day test for heterogeneity of odds ratios to test whether outcomes varying substantially between strata were significantly different. For relevant outcomes, we conducted sensitivity analyses in subgroups not taking medications for diabetes, hypertension, and lipids. Lastly, we conducted

an analysis of hemoglobin, hematocrit, and mean corpuscular volume levels by instrument variable status as an additional check on the potential confounding effects of anemia on our association analyses involving HbA1C. For replication in other datasets, we collected summary statistics for the largest available dataset of European or mostly European ancestry for each outcome (Table S3). We used these summary statistics for a two-sample MR, calculating the ratio of each summary statistic coefficient to the exposure-instrument variable coefficient from the UK Biobank. Analyses were done in R 3.6.3. Results were validated with the MendelianRandomization package.

Results

UK Biobank participant characteristics are described in Table 1 and S5.1. At recruitment, 92% of participants consumed alcohol. About half of participants reported drinking alcohol 1-4 times per week, and an additional one fifth of participants reported drinking daily. On average, participants reported drinking 7.7 ($\pm$ 9.4) glasses per week.

Exclusion of those with prior CVD (n = 21,386) yielded a dataset of 481,150 (Table 1). For our observational analysis (Figure S4.1-4S.2, Table S4.3-S4.6), increased alcohol use was directly related to higher systolic and diastolic blood pressure, total cholesterol, HDL, and atrial fibrillation in the fully-adjusted model. We observed a J-shape association (compared with no drinking, lower coefficient/odds ratio/hazard ratio with moderate drinking, but higher with heavy drinking) with BMI, waist circumference, body fat percentage, stroke (total, ischemic, and hemorrhagic), and all-cause death. Triglycerides, type 2 diabetes, myocardial infarction, heart failure and total cardiovascular disease also had a J-shape association, but with lower betas/odds ratio/hazard ratio at all drinking levels compared with non-drinkers. Alcohol was inversely associated with HbA1C. No pattern was observed between alcohol and LDL.

The Arg47His *ADH1B* variant was found in 4.4% of individuals in the UK Biobank, with only 188 homozygous for the variant. Our MR analysis (n =337,484) showed that those with the wildtype consumed 2.1 drinks/week more than carriers of the Arg47His variant in *ADH1B* (7,127 g/year or 8.2 glasses/week for wildtype vs 5,276 g/year or 6.1 glasses/week for carriers; F = 718) (Table 2). The two-stage least squares analysis showed that alcohol intake equivalent to one additional glass of wine per day was causally associated with higher systolic blood pressure (2.99 mmHg), BMI (0.87 kg/m²), waist circumference (1.34 cm), body fat percentage (1.68%), cholesterol (0.160 mmol/L), LDL (0.155 mmol/L). Triglycerides (-0.059 mmol/L) and HbA1C (-0.420 mmol/mol) were significantly lower while diastolic blood pressure and HDL showed no difference. For disease events, one additional drink/week corresponded to higher risk of MI (OR = 1.50), all stroke (OR = 1.52), any cardiovascular disease (OR = 1.43), and all-cause death (OR = 1.41), while other disease events showed no change.

Drinking varied by sex (men: 11.1 glasses/week vs. women: 5.4 glasses/week) and by smoking status (current smokers: 9.8 glasses/week vs. never-smokers: 6.5 glasses/week) in stratified analyses (Table 2). One additional drink per day corresponded to higher systolic blood

pressure, BMI, waist circumference, body fat percentage, and LDL in all groups. Men additionally had higher risk of heart failure (OR=1.76), atrial fibrillation (OR=1.35), and type 2 diabetes (OR=1.31) with one additional drink per day, while there was no difference in risk for these diseases in women. Women did not have any increase in myocardial infarction with alcohol use. We measured statistical evidence for heterogeneity of the OR between men and women for myocardial infarction ($p=0.070$), heart failure ($p=0.048$), atrial fibrillation ($p=0.041$), type 2 diabetes ($p=0.068$), all CVD ($p=0.013$), and all-cause death ($p=0.015$).

Sensitivity analyses in subgroups not taking medications for diabetes, hypertension, and lipids showed negligible differences in results for HbA1C, systolic/diastolic blood pressure, and LDL/triglycerides, respectively (S5.2). Analysis of blood count data by instrument variable showed that those with the wildtype, who drink more, had a lower hemoglobin (-0.02 g/dL, $p=0.0018$) and hematocrit (-0.09% , $p=0.0024$), and a higher mean corpuscular volume ($+0.27$ fL, $p=2.4 \times 10^{-13}$) (Table S5.3).

In summary statistics from external datasets, alcohol was predictive of stroke and ischemic stroke (MEGASTROKE), type 2 diabetes (DIAMANTE), BMI (GIANT-UK Biobank meta-analysis), and waist circumference (EXTEND) (Figure 1).

Discussion

Our principal analysis within the UK Biobank suggests that alcohol is causally associated not only with a range of adverse cardiovascular related outcomes such as myocardial infarction, stroke, and all-cause death, but also multiple traditional risk factors for these outcomes that likely mediate these observed effects including hypertension (systolic blood pressure), obesity (waist circumference, body fat percentage), and atherogenic dyslipidemia (cholesterol, LDL). Our findings in the UK Biobank were further supported by analyses involving external datasets for a subset of these outcomes including obesity (BMI, waist circumference), stroke, and Type 2 diabetes. Our MR analyses gave discrepant results when compared to the analogous observational analysis for these phenotypes, which suggests the presence of residual confounding from unmeasured factors in observational analysis.

Two findings in our analyses are inconsistent with the hypothesis of a causal negative effect on cardiometabolic outcomes mediated through risk factors. First, we found alcohol to be causally associated with a lower level of triglycerides in the UK Biobank, which would be expected to reduce the risk of atherosclerosis related outcomes. We note this finding is contrary to what has been observed experimentally [26]; but consistent with other MR studies [27-29]. Although multiple MR studies suggest triglycerides are causally associated with CVD, clinical trials of triglyceride-lowering agents have not consistently supported this relationship leading to the conclusion that how triglycerides are lowered plays an important role in whether that lowering translates to cardiovascular benefit. Second, we found alcohol to be inversely associated with HbA1C which would be expected to reduce the risk of Type 2 diabetes. We suspect this counterintuitive association observed may be a technical artifact driven by the presence of a

mild (possibly nutritional) macrocytosis we observed among participants not carrying the minor allele at rs1229984 that biases HgA1C levels downwards without truly altering the risk of diabetes[30, 31].

Our stratified analyses suggest that alcohol is more harmful for men than for women for nearly all outcomes. We observed the largest differences in the point estimates of the harmful effect for heart-related outcomes (myocardial infarction, heart failure, and atrial fibrillation) with a smaller difference observed for type 2 diabetes. For most outcomes, the point estimate of effect of alcohol for women was near 1. Tests for heterogeneity of odds ratios for outcomes which appeared to differ between men and women were not definitive as to whether a true difference exists but strongly suggestive. Larger samples sizes are needed to more reliably document a statistically significant modification of effect of alcohol between men and women. If confirmed, these findings would suggest that causal negative effects of alcohol may only begin to express themselves at a higher consumption level despite differences in body surface area and rate of metabolism between females and males. We did not observe the same trend between our smoking subgroup analysis where the effect of drinking did not differ substantially between smokers and non-smokers for most outcomes.

Our findings are largely consistent with the existing literature of MR studies of alcohol and cardiovascular risk factors and outcomes which have found alcohol to be harmful for CVD related outcomes and most cardiometabolic risk factors [27-29, 32, 33]. For example, the first large MR study of risk factors and outcomes using data gathered from over 56 cohort studies of individuals of European ancestry and the same genetic instrument in *ADH1B* found moderate alcohol use to be associated with higher systolic blood pressure, waist circumference, BMI, LDL, and risk of coronary heart disease [28]. Another smaller MR study in Danes also found a direct association with a higher BMI [27]. A study of the China Kadoorie biobank (>500,000) used a combination of instruments in both *ALDH2* and *ADH1B* found alcohol to be positively associated with increasing systolic blood pressure, HDL, ischemic stroke, and intracerebral hemorrhage, but no effect was found for myocardial infarction [32]. Another recent study of alcohol and CVD outcomes in the UK Biobank using a multi-SNP instrument variable found an increase in blood pressure, stroke, and peripheral artery disease [29]. The inverse association of alcohol with triglycerides that we observed has also been shown in several other MR studies[27-29]. Diabetes has previously been found to have no association with alcohol in an MR meta-analysis (>14,000 cases) as instrumented by the same variant we used [28]. However, another study in a Chinese population using the *ALDH2* rs671 variant, which has a more profound effect on alcohol intake, found a higher risk of diabetes with increasing alcohol [33]. Unique contributions of our study include the identification of the harmful effects of alcohol on body fat percentage and all-cause death. Our study also adds to the existing literature by showing sex-stratified differences which merit further investigation.

Major strengths of our study include the use of a single SNP as a genetic instrument to predict causality of alcohol consumption combined with a large sample size. Using a single instrument within an alcohol metabolizing gene that is strongly associated with the exposure maximizes the probability that the all assumptions of an MR study have been met and the results are

accurately reflecting a relationship that is free from any residual confounding [34]. A potential weakness may be the generalizability of our study given the well-established healthy cohort effect observed for the UK Biobank [35], although the healthy cohort may have helped by minimizing the inclusion of subjects with alcohol use disorder and/or moderate but still high-risk use of alcohol (e.g. binge drinkers). Our results are also limited to UK residents and therefore may vary somewhat in other populations although MR studies to date in other populations including Chinese are largely consistent with our findings [27, 28, 32, 33]. More research is needed on the determination of the causal effects of alcohol consumption in race/ethnic groups other than Europeans and East Asians to determine if effects observed to date generalize to all major race/ethnic groups.

Proposed mechanisms for the negative effect of alcohol on cardiometabolic disease include a pathway via raised blood pressure [36] and atherogenic lipids [37] as well as increased adiposity and subsequent risk of Type 2 diabetes, consistent with our MR findings and those of others. Raised HDL has been proposed as a protective factor but our MR results do not support that such elevations are directly related to alcohol among a population of predominantly moderate alcohol users. The same relationship with HDL has been observed in other MR studies [28, 29, 33]. Additionally, multiple lines of evidence now suggest that HDL levels are not causally associated with heart disease [17, 18] but instead serve as a marker of a variety of factors that may or may not affect the risk of CVD. In this context, one can speculate that physical activity raises HDL in a health-promoting way [38], while alcohol consumption does not. Further harm of alcohol for stroke could come from alcohol induced thrombocytopenia (hemorrhagic stroke) and reduced fibrinolysis (ischemic stroke) with alcohol use [39].

In conclusion, our analysis adds to the mounting evidence using MR that alcohol use does not improve cardiovascular health even in moderate amounts and likely worsens it when all other factors are considered. Given this evidence and the fact that alcohol is implicated in a number of public health concerns not directly related to cardiometabolic health, including addictive disorders, accidents, suicides, liver disease, and various types of cancers (e.g. esophageal, gastrointestinal, head and neck) [40], we believe it is time to reconsider current public health recommendations in the US and other countries which suggest that up to two drinks/day for men and one drink/day for women is not harmful and possibly beneficial to cardiovascular health [41]. This reconsideration is also supported by a more recent observational study that considered the full spectrum of alcohol related health consequences across the entire age spectrum and concluded that the level of consumption that minimizes health loss is zero [40]. Properly conducted randomized control trials [42] may one day more reliably inform us on this matter but, until that time comes, Mendelian randomization analyses provides an acceptable alternative to help inform health policy in this respect.

Tables and figures

Table 1

Summary of characteristics of UK Biobank participants in datasets used for analyses, n (%) or mean(standard deviation)

Variable	Total dataset	Observational analysis	Mendelian randomization
n	502536	481150	337484
Sex			
Female	273402 (54.4)	267459 (55.6)	181236 (53.7)
Male	229134 (45.6)	213691 (44.4)	156248 (46.3)
Age (years)	67.3 (8.1)	67 (8.1)	67.6 (8)
Region			
England	445883 (88.7)	427194 (88.8)	297645 (88.2)
Wales	20808 (4.1)	19936 (4.1)	14824 (4.4)
Scotland	35845 (7.1)	34020 (7.1)	25015 (7.4)
Townsend index	-1.3 (3.1)	-1.3 (3.1)	-1.6 (2.9)
Ethnic group			
White	472725 (94.1)	452534 (94.1)	337484 (100)
Asian or Asian British	11456 (2.3)	10847 (2.3)	0 (0)
Black or Black British	8061 (1.6)	7863 (1.6)	0 (0)
Mixed or other	7517 (1.5)	7279 (1.5)	0 (0)
Don't know/refused	2777 (0.6)	2627 (0.5)	0 (0)
Smoking status			
Never-smoker	273537 (54.4)	265259 (55.1)	183826 (54.5)
Current smoker	52979 (10.5)	50453 (10.5)	33977 (10.1)
Former smoker	173070 (34.4)	162687 (33.8)	118505 (35.1)
No response	2950 (0.6)	2751 (0.6)	1176 (0.3)
Drinking status			

Never-drinker	22388 (4.5)	21234 (4.4)	10392 (3.1)
Current drinker	460386 (91.6)	441728 (91.8)	315257 (93.4)
Former drinker	18108 (3.6)	16631 (3.5)	11543 (3.4)
No response	1654 (0.3)	1557 (0.3)	292 (0.1)
Drinking frequency			
Daily or almost daily	101774 (20.3)	97438 (20.3)	72270 (21.4)
Three or four times a week	115445 (23)	111123 (23.1)	81462 (24.1)
Once or twice a week	129297 (25.7)	124157 (25.8)	88747 (26.3)
One to three times a month	55858 (11.1)	53724 (11.2)	37367 (11.1)
Special occasions only	58012 (11.5)	55286 (11.5)	35411 (10.5)
Never	40648 (8.1)	38009 (7.9)	21991 (6.5)
No response	1502 (0.3)	1413 (0.3)	236 (0.1)
Alcohol (weekly equivalent glasses of wine)	7.7 (9.4)	7.7 (9.4)	8.1 (9.5)
Systolic blood pressure (mmHg)	139.7 (19.7)	139.7 (19.7)	140.2 (19.7)
Diastolic blood pressure (mmHg)	82.2 (10.7)	82.3 (10.7)	82.2 (10.7)
Body mass index (kg/m ²)	27.4 (4.8)	27.4 (4.8)	27.4 (4.7)
Waist circumference (cm)	90.3 (13.5)	90 (13.4)	90.3 (13.5)
Body fat percentage	31.5 (8.5)	31.5 (8.6)	31.4 (8.5)
Cholesterol (mmol/L)	5.7 (1.1)	5.7 (1.1)	5.7 (1.1)
LDL (mmol/L)	3.6 (0.9)	3.6 (0.9)	3.6 (0.9)
HDL (mmol/L)	1.4 (0.4)	1.5 (0.4)	1.5 (0.4)
Triglycerides (mmol/L)	1.7 (1)	1.7 (1)	1.8 (1)
HbA1c (mmol/mol)	36.1 (6.8)	36 (6.5)	36 (6.5)
Glucose (mmol/L)	5.1 (1.2)	5.1 (1.2)	5.1 (1.2)
Type 2 diabetes	25217 (5)	22083 (4.6)	15493 (4.6)
Coronary heart disease	24047 (4.8)	11297 (2.3)	16102 (4.8)
All stroke	11785 (2.3)	6857 (1.4)	8044 (2.4)
Ischemic stroke	5081 (1)	3217 (0.7)	3427 (1)
Hemorrhagic stroke	2814 (0.6)	1608 (0.3)	1877 (0.6)
Heart failure	8956 (1.8)	5128 (1.1)	5921 (1.8)

Atrial fibrillation	22197 (4.4)	14292 (3)	15483 (4.6)
Any cardiovascular disease	52219 (10.4)	30833 (6.4)	35499 (10.5)
All-cause death	20284 (4)	17635 (3.7)	13700 (4.1)
ADH1B status			
Wildtype	458807 (91.3)	439084 (91.3)	322519 (95.6)
Carrier	26534 (5.3)	25593 (5.3)	14777 (4.4)
Homozygous minor allele	1979 (0.4)	1928 (0.4)	188 (0.1)

Table 2

Mean alcohol consumption in equivalent glasses of wine per week by group and ADH1B status.

Group	Wildtype, glasses/week	Variant, glasses/week	Increase for wild type, glasses/week
all	8.2	6.1	2.1
male	11.2	8.4	2.8
female	5.5	3.9	1.6
current smoker	11.1	7.6	3.5
never-smoker	6.5	4.6	1.9

Figure 1

See separate PDFs

Caption title: Results from Mendelian randomization of outcome variables in UK Biobank and external datasets

Caption: Significant results shown in black with circles; non-significant results shown in gray with squares.

Figure 1a: Mendelian randomization results for blood pressure and anthropometric measures

Figure 1b: Mendelian randomization results for biochemistry variables

Figure 1c: Mendelian randomization results for disease outcomes and death

Figure 2

See separate PDFs

Caption title: Results from Mendelian randomization of outcome variables in UK Biobank stratified by sex and smoking status

Caption: Significant results shown in black with circles; non-significant results shown in gray with squares.

Figure 2a: Stratified Mendelian randomization results for blood pressure and anthropometric measures

Figure 2b: Stratified Mendelian randomization results for biochemistry variables

Figure 2c: Stratified Mendelian randomization results for disease outcomes and death

Supplement

Supplemental methods detail

S1. Data transformations

S1.1 Disease events

Disease events were defined according to each of the following ICD codes and extracted from hospital data (using both primary and secondary diagnoses).

Event	ICD-9	ICD-10	OPCS-4
Myocardial infarction	410*, 411*	I20.0, I21*, I22*	K40*, K41*, K42*, K43*, K44*, K45*, K46*, K49*, K50*, K75*
All stroke	430*, 431*, 432*, 433*, 434*, 435*, 436*	I60*, I61*, I62*, I63*, G45*, I64*	n/a
Ischemic stroke	433*, 434*	I63*	n/a
Hemorrhagic stroke	430*, 431*, 432*	I60*, I61*, I62*	n/a
Heart failure	428*	I50*	n/a
Atrial fibrillation	427.3*	I48*	K52.1, K62.2, K62.3, K62.4

* Including all subcategories

S1.2 Diabetes

Diabetes was defined using self-reported diabetes (question # 1221, 1222, 1223), self-reported medical conditions (question # 20002), self-reported medications (question # 20003), HbA1C results (question # 30750), age of diagnosis (question # 2976), started insulin within one year of diagnosis (question # 2986), diabetes diagnosed by a doctor (question # 2443), diabetes gestational only (question # 4041).

We flagged individuals who had suspected Type 1 diabetes. We considered individuals to have Type 2 diabetes if they were not flagged for Type 1, and any of the following was true:

- HbA1C exceeded threshold of 48 mmol/mol
- Type 2 diabetes was in their self-reported medical conditions
- Diabetes medications were self-reported
- Diabetes had been diagnosed by a doctor but was not gestational only

We flagged individuals for suspected type 1 diabetes if:

- Type 1 diabetes was in reported conditions, OR
- Diabetes was diagnosed before age 35, OR
- Insulin began within a year of diagnosis.

S2. Observational analysis

In the partially-adjusted model, we used the Townsend index to adjust for socioeconomic status. Ethnicity was grouped by the highest tree-structure group of the 21000 variable. Region was encoded as England, Scotland, or Wales. Antihypertensive and lipid-lowering medications were extracted from variables 6153 and 6177. Diabetes medications came from variables 6153, 6177, and 20003. Sex, age, and smoking status also came from survey data. Fasting time (variable 74) was also used in all biomarker outcome models.

Strikethrough text indicates a variable was not included in the fully-adjusted model.

Outcome	Fully adjusted includes all the partially adjusted plus:
BMI, waist circumference, body fat percentage	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering
SBP and DBP	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering
Type 2 diabetes	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering
Cholesterol, LDL, HDL, triglycerides	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering
HBA1C	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering
Heart disease events (CHD, stroke, etc)	HbA1c, diabetes medications, BMI, waist circumference, SBP, DBP, anti-hypertensive, LDL, HDL, triglycerides, lipid-lowering

S3. Mendelian randomization analysis

Where possible, we utilized the Cardiovascular Disease, Cerebrovascular Disease, and Type 2 Diabetes Knowledge Portals.

Table S3: Data sources for Mendelian randomization. * indicates the source also includes UK Biobank data.

CVDKP = Cardiovascular disease knowledge portal [43],

<http://www.broadcvdi.org/home/portalHome>

CDKP = Cerebrovascular disease knowledge portal [44], <http://cerebrovascularportal.org/>

T2DKP = Type 2 diabetes knowledge portal [45], <http://www.type2diabetesgenetics.org/>

Name	Extracted summary statistics for phenotypes	Population ancestry	n	From
CARDIoGRAMplusC4D with 1000 genomes GWAS meta-analysis [46]	Myocardial infarction	Mixed	184,305	http://www.cardiogramplusc4d.org/data-downloads/
MEGASTROKE [47]	All stroke, Ischemic stroke	Mixed	521,612	CDKP
HERMES Heart Failure GWAS* [48]	Heart failure	European	972,032	CVDKP
2018 AF HRC GWAS [49]	Atrial fibrillation	Mixed	588,190	CVDKP
DIAMANTE T2D GWAS* [50]	Type 2 diabetes	European	898,130	T2DKP
FinnMetSeq exome sequence analysis [51]	Systolic blood pressure, diastolic blood pressure, body fat percentage	European	19,291	T2DKP
MAGIC GWAS [52]	HbA1C	European	5,318	T2DKP
GIANT 2018 BMI, Height exome chip analysis [53]	BMI	European	449,889	https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files
GIANT-UK Biobank GWAS Meta-analysis* [54]	BMI	European	694,649	T2DKP
EXTEND GWAS [55]	Waist circumference	European	7,159	T2DKP
Body fat percentage GWAS [56]	Body fat percentage	Mixed (89,267 European)	100,716	T2DKP
GLGC exome chip analysis [57]	Total cholesterol, LDL, HDL, triglycerides	Mixed (273,050 European)	~300,000	https://my.locuszoom.org/gwas/919709/

Supplemental results

S4. Observational analysis results

All results are compared to a reference of no alcohol consumption

SBP: Systolic blood pressure (mmHg)

DBP: Diastolic blood pressure (mmHg)

BMI: Body mass index (kg/m²)

WAIST: Waist circumference (cm)

BFP: Body fat percentage

CHOL: Cholesterol (mmol/L)

LDL: Low-density lipoprotein (mmol/L)

HDL: High-density lipoprotein (mmol/L)

TG: Triglycerides (mmol/L)

HBA1C: Glycated hemoglobin (mmol/mol)

T2D: type 2 diabetes

MI: myocardial infarction

ALLSTROKE: all types of stroke

ISTROKE: ischemic stroke

HSTROKE: hemorrhagic stroke

HF: heart failure

AFIB: atrial fibrillation

CVD: any cardiovascular disease (MI, ALLSTROKE, ISTROKE, HSTROKE, HF, AFIB)

Death: all-cause death

Figure S4.1: Observational analysis results for effect size for given drinking category (units listed with abbreviations) for fully adjusted model.

Figure S4.2: Observational analysis results for hazard ratio (event outcomes) or odds ratio (type 2 diabetes) for fully adjusted model.

S4.3 Betas and confidence intervals for continuous measures, basic model. Reference: no alcohol consumption.

glasses /day	SBP	DBP	BMI	WAIST	BFP	CHOL	LDL	HDL	TG	HBA1C
>0-1	0.22 (0.07,0.36)	-0.010 (-0.09,0.07)	-1.17 (-1.21,-1.14)	-2.66 (-2.74,-2.57)	-1.11 (-1.15,-1.06)	0.11 (0.10,0.12)	0.03 (0.02,0.04)	0.11 (0.10,0.11)	-0.14 (-0.14,-0.13)	-0.99 (-1.04,-0.94)
>1-2	1.02 (0.86,1.18)	0.72 (0.62,0.81)	-1.40 (-1.44,-1.36)	-3.03 (-3.13,-2.93)	-1.31 (-1.36,-1.25)	0.19 (0.18,0.20)	0.03 (0.02,0.03)	0.20 (0.20,0.21)	-0.19 (-0.20,-0.18)	-1.60 (-1.66,-1.55)
>2-3	3.13 (2.92,3.34)	2.06 (1.94,2.18)	-1.07 (-1.12,-1.02)	-2.06 (-2.19,-1.93)	-0.79 (-0.86,-0.72)	0.28 (0.27,0.29)	0.05 (0.04,0.06)	0.26 (0.26,0.27)	-0.16 (-0.17,-0.15)	-1.82 (-1.89,-1.74)
>3	6.28 (6.05,6.51)	3.85 (3.72,3.98)	-0.69 (-0.74,-0.63)	-0.74 (-0.88,-0.59)	-0.18 (-0.25,-0.10)	0.40 (0.39,0.41)	0.07 (0.06,0.08)	0.34 (0.34,0.35)	-0.08 (-0.09,-0.06)	-1.86 (-1.94,-1.78)

S4.4 Betas and confidence intervals for continuous measures, fully-adjusted model. Reference: no alcohol consumption.

glasses /day	SBP	DBP	BMI	WAIST	BFP	CHOL	LDL	HDL	TG	HBA1C
>0-1	0.72 (0.56,0.87)	0.48 (0.39,0.56)	-0.54 (-0.57,-0.50)	-0.97 (-1.06,-0.88)	-0.35 (-0.39,-0.30)	0.07 (0.06,0.08)	0.01 (0.00,0.02)	0.08 (0.07,0.08)	-0.07 (-0.08,-0.06)	-0.34 (-0.38,-0.29)
>1-2	1.37 (1.19,1.55)	1.21 (1.11,1.31)	-0.39 (-0.43,-0.35)	-0.32 (-0.43,-0.22)	-0.10 (-0.15,-0.04)	0.13 (0.12,0.14)	0.00 (-0.01,0.00)	0.16 (0.16,0.17)	-0.11 (-0.12,-0.10)	-0.70 (-0.75,-0.65)
>2-3	2.91 (2.67,3.14)	2.17 (2.04,2.30)	0.00 (-0.06,0.05)	0.87 (0.74,1.00)	0.49 (0.42,0.57)	0.21 (0.20,0.22)	0.01 (0.00,0.01)	0.23 (0.23,0.24)	-0.11 (-0.12,-0.10)	-0.91 (-0.98,-0.85)
>3	5.01 (4.76,5.26)	3.39 (3.24,3.53)	0.43 (0.37,0.49)	2.38 (2.23,2.52)	1.16 (1.08,1.24)	0.32 (0.30,0.33)	0.02 (0.01,0.03)	0.32 (0.32,0.32)	-0.06 (-0.08,-0.05)	-1.10 (-1.17,-1.02)

S4.5 Odds ratios and confidence intervals for type 2 diabetes, basic model. Reference: no alcohol consumption.

glasses/day	T2D
>0-1	0.59 (0.57,0.61)
>1-2	0.44 (0.42,0.46)
>2-3	0.43 (0.4,0.45)
>3	0.47 (0.45,0.5)

S4.6 Odds ratios and confidence intervals for type 2 diabetes, fully-adjusted model. Reference: no alcohol consumption.

glasses/day	T2D
>0-1	0.81 (0.77,0.84)
>1-2	0.69 (0.65,0.73)
>2-3	0.68 (0.63,0.73)
>3	0.75 (0.7,0.81)

S4.7 Hazard ratios and confidence intervals for binary measures (diseases and events), basic model. Reference: no alcohol consumption.

glasses/day	MI	ALLSTROKE	ISTROKE	HSTROKE	HF	AFIB	CVD	Death
>0-1	0.80 (0.76,0.84)	0.89 (0.84,0.95)	0.85 (0.78,0.93)	0.93 (0.82,1.05)	0.69 (0.64,0.74)	0.88 (0.84,0.92)	0.83 (0.81,0.86)	0.77 (0.74,0.80)
>1-2	0.70 (0.66,0.74)	0.83 (0.78,0.89)	0.86 (0.78,0.95)	0.79 (0.68,0.92)	0.61 (0.56,0.66)	0.89 (0.85,0.94)	0.78 (0.75,0.80)	0.71 (0.68,0.74)
>2-3	0.68 (0.63,0.72)	0.79 (0.72,0.87)	0.75 (0.65,0.86)	0.93 (0.77,1.12)	0.63 (0.57,0.70)	0.94 (0.88,0.99)	0.79 (0.75,0.82)	0.71 (0.67,0.75)
>3	0.69 (0.65,0.74)	0.98 (0.90,1.08)	1.00 (0.88,1.14)	1.07 (0.88,1.29)	0.75 (0.68,0.83)	1.10 (1.04,1.17)	0.88 (0.85,0.92)	0.91 (0.87,0.96)

S4.8 Hazard ratios and confidence intervals for binary measures (diseases and events), fully-adjusted model. Reference: no alcohol consumption.

glasses/day	MI	ALLSTROKE	ISTROKE	HSTROKE	HF	AFIB	CVD	Death
>0-1	0.89 (0.84,0.95)	0.91 (0.85,0.98)	0.87 (0.78,0.97)	0.91 (0.78,1.06)	0.81 (0.74,0.88)	0.98 (0.93,1.03)	0.91 (0.88,0.95)	0.80 (0.76,0.84)
>1-2	0.82 (0.77,0.88)	0.87 (0.80,0.95)	0.93 (0.82,1.05)	0.76 (0.63,0.91)	0.73 (0.66,0.81)	1.00 (0.95,1.07)	0.87 (0.84,0.91)	0.77 (0.73,0.82)
>2-3	0.81 (0.74,0.88)	0.85 (0.76,0.95)	0.81 (0.69,0.95)	1.00 (0.80,1.24)	0.78 (0.68,0.88)	1.04 (0.97,1.12)	0.89 (0.85,0.93)	0.78 (0.73,0.84)
>3	0.85 (0.78,0.92)	1.02 (0.91,1.14)	1.04 (0.89,1.22)	1.00 (0.79,1.26)	0.91 (0.80,1.03)	1.20 (1.11,1.29)	0.99 (0.94,1.05)	1.04 (0.97,1.11)

S5. Mendelian randomization results

S5.1 Characteristics of strata for the Mendelian randomization (MR) analysis

The total column is repeated from Table 1.

Variable	MR - total	MR - male	MR - female	MR - nonsmokers	MR - smokers
n	337484	156248	181236	183826	33977
Sex					
Female	181236 (53.7)	0 (0)	181236 (100)	107418 (58.4)	15577 (45.8)
Male	156248 (46.3)	156248 (100)	0 (0)	76408 (41.6)	18400 (54.2)
Age (years)	67.6 (8)	67.9 (8.1)	67.4 (7.9)	66.9 (8.1)	65.9 (8.1)
Region					
England	297645 (88.2)	138232 (88.5)	159413 (88)	161683 (88)	29350 (86.4)
Wales	14824 (4.4)	6822 (4.4)	8002 (4.4)	8236 (4.5)	1614 (4.8)
Scotland	25015 (7.4)	11194 (7.2)	13821 (7.6)	13907 (7.6)	3013 (8.9)
Townsend index	-1.6 (2.9)	-1.5 (3)	-1.6 (2.9)	-1.9 (2.7)	-0.1 (3.5)
Ethnic group					
White	337484 (100)	156248 (100)	181236 (100)	183826 (100)	33977 (100)
Asian or Asian British	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Black or Black British	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Mixed or other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know/refused	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Smoking status					
Never-smoker	183826 (54.5)	76408 (48.9)	107418 (59.3)	183826 (100)	0 (0)
Current smoker	33977 (10.1)	18400 (11.8)	15577 (8.6)	0 (0)	33977 (100)
Former smoker	118505 (35.1)	60883 (39)	57622 (31.8)	0 (0)	0 (0)
No response	1176 (0.3)	557 (0.4)	619 (0.3)	0 (0)	0 (0)
Drinking status					
Never-drinker	10392 (3.1)	2623 (1.7)	7769 (4.3)	8234 (4.5)	674 (2)
Current drinker	315257 (93.4)	148479 (95)	166778 (92)	170381 (92.7)	31430 (92.5)
Former drinker	11543 (3.4)	5017 (3.2)	6526 (3.6)	5084 (2.8)	1806 (5.3)
No response	292 (0.1)	129 (0.1)	163 (0.1)	127 (0.1)	67 (0.2)
Drinking frequency					
Daily or almost daily	72270 (21.4)	41339 (26.5)	30931 (17.1)	30020 (16.3)	9136 (26.9)
Three or four times a week	81462 (24.1)	42266 (27.1)	39196 (21.6)	44049 (24)	6542 (19.3)
Once or twice a week	88747 (26.3)	40983 (26.2)	47764 (26.4)	52425 (28.5)	7865 (23.1)
One to three times a month	37367 (11.1)	13662 (8.7)	23705 (13.1)	22816 (12.4)	3720 (10.9)
Special occasions only	35411 (10.5)	10229 (6.5)	25182 (13.9)	21071 (11.5)	4167 (12.3)

Never	21991 (6.5)	7656 (4.9)	14335 (7.9)	13354 (7.3)	2491 (7.3)
No response	236 (0.1)	113 (0.1)	123 (0.1)	91 (0)	56 (0.2)
Alcohol (weekly equivalent glasses of wine)	8.1 (9.5)	11.1 (11.2)	5.4 (6.6)	6.5 (7.8)	10.9 (13.3)
Systolic blood pressure (mmHg)	140.2 (19.7)	143.2 (18.5)	137.6 (20.3)	139.7 (19.5)	137.5 (19.5)
Diastolic blood pressure (mmHg)	82.2 (10.7)	84.1 (10.5)	80.6 (10.5)	82.2 (10.6)	81.6 (10.9)
Body mass index (kg/m ²)	27.4 (4.7)	27.8 (4.2)	27 (5.1)	27.1 (4.7)	27.1 (4.8)
Waist circumference (cm)	90.3 (13.5)	97 (11.3)	84.6 (12.5)	88.7 (13.2)	91.2 (13.5)
Body fat percentage	31.4 (8.5)	25.3 (5.8)	36.6 (6.9)	31.4 (8.6)	29.9 (8.6)
Cholesterol (mmol/L)	5.7 (1.1)	5.5 (1.1)	5.9 (1.1)	5.7 (1.1)	5.7 (1.2)
LDL (mmol/L)	3.6 (0.9)	3.5 (0.9)	3.6 (0.9)	3.6 (0.9)	3.6 (0.9)
HDL (mmol/L)	1.5 (0.4)	1.3 (0.3)	1.6 (0.4)	1.5 (0.4)	1.4 (0.4)
Triglycerides (mmol/L)	1.8 (1)	2 (1.1)	1.6 (0.9)	1.7 (1)	2 (1.2)
HbA1c (mmol/mol)	36 (6.5)	36.3 (7.3)	35.7 (5.7)	35.5 (6)	37.1 (7.2)
Glucose (mmol/L)	5.1 (1.2)	5.2 (1.4)	5.1 (1)	5.1 (1.1)	5.1 (1.2)
Type 2 diabetes	15493 (4.6)	9879 (6.3)	5614 (3.1)	6402 (3.5)	1715 (5)
Coronary heart disease	16102 (4.8)	12260 (7.8)	3842 (2.1)	6057 (3.3)	2274 (6.7)
All stroke	8044 (2.4)	4825 (3.1)	3219 (1.8)	3498 (1.9)	1193 (3.5)

Ischemic stroke	3427 (1)	2195 (1.4)	1232 (0.7)	1434 (0.8)	561 (1.7)
Hemorrhagic stroke	1877 (0.6)	1002 (0.6)	875 (0.5)	811 (0.4)	278 (0.8)
Heart failure	5921 (1.8)	4116 (2.6)	1805 (1)	2145 (1.2)	920 (2.7)
Atrial fibrillation	15483 (4.6)	10425 (6.7)	5058 (2.8)	6766 (3.7)	1530 (4.5)
Any cardiovascular disease	35499 (10.5)	24023 (15.4)	11476 (6.3)	14911 (8.1)	4532 (13.3)
All-cause death	13700 (4.1)	8410 (5.4)	5290 (2.9)	5102 (2.8)	2696 (7.9)
ADH1B status					
Wildtype	322519 (95.6)	149158 (95.5)	173361 (95.7)	175669 (95.6)	32518 (95.7)
Carrier	14777 (4.4)	7013 (4.5)	7764 (4.3)	8056 (4.4)	1441 (4.2)
Homozygous minor allele	188 (0.1)	77 (0)	111 (0.1)	101 (0.1)	18 (0.1)

S5.2 Sensitivity analysis: Meds for diabetes, hypertension, and lipids

Our sensitivity analysis showed little difference in the overall outcome and no difference in the ultimate finding when excluding individuals with medications for diabetes, hypertension, or lowering of lipids.

Group	HbA1C effect for +1 drink/day
Everyone (n=337,484)	-0.420 mmol/mol (-0.781, -0.059)
Diabetes medication takers excluded (n=325,466; 96%)	-0.412 mmol/mol (-0.684, -0.140)

Group	Systolic BP effect for +1 drink/day	Diastolic BP effect for +1 drink/day
Everyone (n=337,484)	2.99 mmHg (1.90, 4.09)	0.492 mmHg (-0.102, 1.09)
Hypertensive medication takers excluded (n=267,379; 79%)	2.77 mmHg (1.45, 4.09)	0.573 mmHg (-0.149, 1.30)

Group	LDL effect for +1 drink/day	TG effect for +1 drink/day	HDL effect for +1 drink/day
Everyone (n=337,484)	0.155 mmol/L (0.107, 0.204)	-0.059 mmol/L (-0.012, -0.002)	0.0013 mmol/L (-0.021, 0.023)
Lipid lowering medication takers excluded (n=278,875; 83%)	0.219 mmol/L (0.164, 0.273)	-0.080 mmol/L (-0.147, -0.013)	0.0095 mmol/L (-0.017, 0.036)

S5.3 Additional analysis of blood count data by instrument variable group

Variable	Heterozygous + homozygous group	Wildtype	p-value	F statistic
Hemoglobin (g/dL)	14.23	14.21	0.0179	5.6
Hematocrit (%)	41.24	41.15	0.00237	9.2
Mean corpuscular volume (fL)	91.08	91.35	2.37e-13	53.7

1. Grant, B.F., et al., *Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions*. JAMA Psychiatry, 2017. **74**(9): p. 911-923.
2. NHS. *Part 4: Drinking behaviours among adults*. Statistics on Alcohol, England 2020 [cited 2020 October 8]; Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-alcohol/2020/part-4>.
3. Koppes, L.L., et al., *Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies*. Diabetes Care, 2005. **28**(3): p. 719-25.
4. Li, X.H., et al., *Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose-response meta-analysis*. Am J Clin Nutr, 2016. **103**(3): p. 818-29.
5. Friedman, L.A. and A.W. Kimball, *Coronary heart disease mortality and alcohol consumption in Framingham*. Am J Epidemiol, 1986. **124**(3): p. 481-9.
6. Gordon, T. and W.B. Kannel, *Drinking habits and cardiovascular disease: the Framingham Study*. Am Heart J, 1983. **105**(4): p. 667-73.
7. Wood, A.M., et al., *Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies*. Lancet, 2018. **391**(10129): p. 1513-1523.
8. Sacco, R.L., et al., *The protective effect of moderate alcohol consumption on ischemic stroke*. Jama, 1999. **281**(1): p. 53-60.
9. Reynolds, K., et al., *Alcohol consumption and risk of stroke: a meta-analysis*. Jama, 2003. **289**(5): p. 579-88.
10. Stampfer, M.J., et al., *A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women*. N Engl J Med, 1988. **319**(5): p. 267-73.
11. Gallagher, C., et al., *Alcohol and incident atrial fibrillation - A systematic review and meta-analysis*. Int J Cardiol, 2017. **246**: p. 46-52.
12. Walsh, C.R., et al., *Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study*. Ann Intern Med, 2002. **136**(3): p. 181-91.
13. Marmot, M.G., et al., *Alcohol and blood pressure: the INTERSALT study*. Bmj, 1994. **308**(6939): p. 1263-7.
14. Castelli, W.P., et al., *Alcohol and blood lipids. The cooperative lipoprotein phenotyping study*. Lancet, 1977. **2**(8030): p. 153-5.
15. Hartung, G.H., et al., *Effect of alcohol intake on high-density lipoprotein cholesterol levels in runners and inactive men*. Jama, 1983. **249**(6): p. 747-50.
16. Schrieks, I.C., et al., *The effect of alcohol consumption on insulin sensitivity and glycemic status: a systematic review and meta-analysis of intervention studies*. Diabetes Care, 2015. **38**(4): p. 723-32.
17. Voight, B.F., et al., *Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study*. Lancet, 2012. **380**(9841): p. 572-80.
18. Rosenson, R.S., *The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?* Arterioscler Thromb Vasc Biol, 2016. **36**(5): p. 777-82.
19. Armitage, J., M.V. Holmes, and D. Preiss, *Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week*. J Am Coll Cardiol, 2019. **73**(4): p. 477-487.
20. Emberson, J.R. and D.A. Bennett, *Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?* Vasc Health Risk Manag, 2006. **2**(3): p. 239-49.
21. Sesso, H.D., et al., *Alcohol consumption and the risk of hypertension in women and men*. Hypertension, 2008. **51**(4): p. 1080-7.

22. Sudlow, C., et al., *UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age*. PLoS Med, 2015. **12**(3): p. e1001779.
23. NHS. *Alcohol Units*. [cited 2017 November 29]; Available from: <https://www.nhs.uk/live-well/alcohol-support/calculating-alcohol-units/>.
24. Karczewski, K.J., et al., *The mutational constraint spectrum quantified from variation in 141,456 humans*. Nature, 2020. **581**(7809): p. 434-443.
25. *Genome Aggregation Database*. [cited 2020 October 24]; Available from: https://gnomad.broadinstitute.org/variant/4-100239319-T-C?dataset=gnomad_r2_1.
26. Rimm, E.B., et al., *Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors*. Bmj, 1999. **319**(7224): p. 1523-8.
27. Lawlor, D.A., et al., *Exploring causal associations between alcohol and coronary heart disease risk factors: findings from a Mendelian randomization study in the Copenhagen General Population Study*. Eur Heart J, 2013. **34**(32): p. 2519-28.
28. Holmes, M.V., et al., *Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data*. Bmj, 2014. **349**: p. g4164.
29. Larsson, S.C., et al., *Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study*. Circ Genom Precis Med, 2020. **13**(3): p. e002814.
30. Lindenbaum, J. and M.J. Roman, *Nutritional anemia in alcoholism*. Am J Clin Nutr, 1980. **33**(12): p. 2727-35.
31. Sakamoto, N., et al., *Associations of anemia and hemoglobin with hemoglobin A1c among non-diabetic workers in Japan*. J Diabetes Investig, 2020. **11**(3): p. 719-725.
32. Millwood, I.Y., et al., *Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China*. Lancet, 2019. **393**(10183): p. 1831-1842.
33. Peng, M., et al., *Alcohol consumption and diabetes risk in a Chinese population: a Mendelian randomization analysis*. Addiction, 2019. **114**(3): p. 436-449.
34. Davey Smith, G. and G. Hemani, *Mendelian randomization: genetic anchors for causal inference in epidemiological studies*. Hum Mol Genet, 2014. **23**(R1): p. R89-98.
35. Fry, A., et al., *Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population*. Am J Epidemiol, 2017. **186**(9): p. 1026-1034.
36. Grogan, J.R. and M.S. Kochar, *Alcohol and hypertension*. Arch Fam Med, 1994. **3**(2): p. 150-4.
37. Brien, S.E., et al., *Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies*. Bmj, 2011. **342**: p. d636.
38. Wood, P.D., et al., *Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise*. N Engl J Med, 1988. **319**(18): p. 1173-9.
39. Ballard, H.S., *The hematological complications of alcoholism*. Alcohol Health Res World, 1997. **21**(1): p. 42-52.
40. *Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016*. Lancet, 2018. **392**(10152): p. 1015-1035.
41. Office of Disease Prevention and Health Promotion. *Alcohol*. Dietary Guidelines 2015-2020 [cited 2020 October 12]; Available from: <https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/appendix-9/>.

42. Spiegelman, D., et al., *The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk*. Eur J Prev Cardiol, 2020: p. 2047487320912376.
43. *Cardiovascular Disease Knowledge Portal*. [cited 2020 February 7]; Available from: <http://www.broadcvdi.org/home/portalHome>.
44. *Cerebrovascular Disease Knowledge Portal, NINDS grant # 1R24NS092983*. [cited 2020 February 7]; Available from: <http://www.cerebrovascularportal.org/home/portalHome>.
45. *Type 2 Diabetes Knowledge Portal*. [cited 2020 February 7]; Available from: <http://www.type2diabetesgenetics.org/>.
46. Nikpay, M., et al., *A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease*. Nat Genet, 2015. **47**(10): p. 1121-1130.
47. Malik, R., et al., *Multi-ancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes*. Nat Genet, 2018. **50**(4): p. 524-537.
48. Shah, S., et al., *Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure*. Nat Commun, 2020. **11**(1): p. 163.
49. Roselli, C., et al., *Multi-ethnic genome-wide association study for atrial fibrillation*. Nat Genet, 2018. **50**(9): p. 1225-1233.
50. Mahajan, A., et al., *Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps*. Nat Genet, 2018. **50**(11): p. 1505-1513.
51. Locke, A.E., et al., *Exome sequencing of Finnish isolates enhances rare-variant association power*. Nature, 2019. **572**(7769): p. 323-328.
52. Soranzo, N., et al., *Common variants at 10 genomic loci influence hemoglobin A_{1c} levels via glycemic and nonglycemic pathways*. Diabetes, 2010. **59**(12): p. 3229-39.
53. Turcot, V., et al., *Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity*. Nat Genet, 2018. **50**(1): p. 26-41.
54. Pulit, S.L., et al., *Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry*. Hum Mol Genet, 2019. **28**(1): p. 166-174.
55. Accelerating Medicines Partnership. Type 2 Diabetes Knowledge Portal News 2018 [cited 2020 October 6]; Available from: <http://t2d-genetics-portal.blogspot.com/2018/02/federation-brings-three-new-datasets-to.html>.
56. Lu, Y., et al., *New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk*. Nat Commun, 2016. **7**: p. 10495.
57. Liu, D.J., et al., *Exome-wide association study of plasma lipids in >300,000 individuals*. Nat Genet, 2017. **49**(12): p. 1758-1766.

Figure 1a: Effect of 1 additional drink/day

Systolic blood pressure (mmHg)

UK Biobank 2.99 [1.90, 4.09]

FinnMetSeq -0.08 [-0.57, 0.41]

Diastolic blood pressure (mmHg)

UK Biobank 0.49 [-0.10, 1.09]

FinnMetSeq -0.34 [-0.83, 0.15]

Body mass index (kg/m²)

UK Biobank 0.87 [0.61, 1.13]

GIANT 0.03 [-0.11, 0.18]

GIANT-UK Biobank MA 0.10 [0.07, 0.13]

Waist circumference (cm)

UK Biobank 1.34 [0.61, 2.07]

EXTEND GWAS 0.46 [0.13, 0.79]

Body fat percentage

UK Biobank 1.68 [1.21, 2.14]

BFP GWAS -0.07 [-0.27, 0.13]

FinnMetSeq -0.45 [-1.09, 0.20]

Figure 1a

Figure 1b: Effect of 1 additional drink/day

Cholesterol (mmol/L)

UK Biobank 0.16 [0.10, 0.22]

GLGC -0.04 [-0.34, 0.26]

LDL (mmol/L)

UK Biobank 0.16 [0.11, 0.20]

GLGC 0.00 [-0.30, 0.30]

HDL (mmol/L)

UK Biobank 0.00 [-0.02, 0.02]

GLGC 0.20 [-0.10, 0.50]

Triglycerides (mmol/L)

UK Biobank -0.06 [-0.12, 0.00]

GLGC -0.26 [-0.56, 0.03]

HbA1C (mmol/mol)

UK Biobank -0.42 [-0.78, -0.06]

MAGIC -0.10 [-0.41, 0.21]

Figure 1b

Figure 1c: Effect of 1 additional drink/day

Myocardial infarction

UK Biobank 1.50 [1.15, 1.96]

CARDIoGRAMplusC4D GWAS 1.11 [0.97, 1.27]

Stroke

UK Biobank 1.52 [1.04, 2.21]

MEGASTROKE 1.14 [1.03, 1.26]

Ischemic stroke

UK Biobank 1.33 [0.76, 2.33]

MEGASTROKE 1.14 [1.02, 1.27]

Hemorrhagic stroke

UK Biobank 1.82 [0.83, 4.01]

Heart failure

UK Biobank 1.50 [0.97, 2.31]

HERMES GWAS 1.14 [0.95, 1.37]

Atrial fibrillation

UK Biobank 1.27 [0.97, 1.65]

AF HRC 2018 GWAS 1.07 [0.96, 1.18]

Type 2 diabetes

UK Biobank 1.26 [0.97, 1.65]

DIAMANTE T2D GWAS 1.25 [1.10, 1.43]

Any cardiovascular disease

UK Biobank 1.43 [1.19, 1.72]

All-cause death

UK Biobank 1.41 [1.06, 1.88]

Figure 1c

Figure 2a: Effect of 1 additional drink/day

Systolic blood pressure (mmHg)

all	2.99 [1.90, 4.09]
male	2.82 [1.69, 3.95]
female	3.54 [1.52, 5.56]
current smokers	3.02 [0.92, 5.12]
never-smokers	2.26 [0.58, 3.94]

Diastolic blood pressure (mmHg)

all	0.49 [-0.10, 1.09]
male	0.77 [0.13, 1.42]
female	0.33 [-0.72, 1.38]
current smokers	1.66 [0.49, 2.83]
never-smokers	0.44 [-0.47, 1.36]

Body mass index (kg/m^2)

all	0.87 [0.61, 1.13]
male	0.79 [0.54, 1.04]
female	1.00 [0.50, 1.50]
current smokers	0.72 [0.22, 1.22]
never-smokers	0.85 [0.45, 1.24]

Waist circumference (cm)

all	1.34 [0.61, 2.07]
male	1.66 [0.99, 2.34]
female	1.87 [0.66, 3.08]
current smokers	1.47 [0.06, 2.87]
never-smokers	1.21 [0.11, 2.30]

Body fat percentage

all	1.68 [1.21, 2.14]
male	1.19 [0.84, 1.53]
female	1.23 [0.56, 1.91]
current smokers	1.17 [0.26, 2.08]
never-smokers	1.58 [0.85, 2.31]

Figure 2a

Figure 2b: Effect of 1 additional drink/day

Cholesterol (mmol/L)

all	0.16 [0.10, 0.22]
male	0.17 [0.10, 0.24]
female	0.10 [−0.01, 0.22]
current smokers	0.10 [−0.03, 0.22]
never-smokers	0.10 [0.00, 0.20]

LDL (mmol/L)

all	0.16 [0.11, 0.20]
male	0.16 [0.11, 0.21]
female	0.12 [0.04, 0.21]
current smokers	0.07 [−0.03, 0.16]
never-smokers	0.11 [0.04, 0.18]

HDL (mmol/L)

all	0.00 [−0.02, 0.02]
male	0.00 [−0.02, 0.02]
female	−0.01 [−0.05, 0.03]
current smokers	0.05 [0.01, 0.09]
never-smokers	−0.02 [−0.05, 0.02]

Triglycerides (mmol/L)

all	−0.06 [−0.12, 0.00]
male	−0.02 [−0.09, 0.05]
female	−0.08 [−0.17, 0.00]
current smokers	−0.10 [−0.22, 0.03]
never-smokers	−0.02 [−0.10, 0.06]

HbA1C (mmol/mol)

all	−0.42 [−0.78, −0.06]
male	−0.09 [−0.53, 0.36]
female	−0.84 [−1.41, −0.27]
current smokers	−0.63 [−1.40, 0.14]
never-smokers	−0.59 [−1.10, −0.08]

Figure 2b

Figure 2c: Effect of 1 additional drink/day

Myocardial infarction

all	1.50	[1.15, 1.96]
male	1.58	[1.24, 2.00]
female	1.06	[0.54, 2.08]
current smokers	1.09	[0.71, 1.66]
never-smokers	1.66	[1.01, 2.73]

Stroke

all	1.52	[1.04, 2.21]
male	1.48	[1.03, 2.15]
female	1.50	[0.70, 3.23]
current smokers	1.15	[0.64, 2.06]
never-smokers	1.47	[0.78, 2.78]

Ischemic stroke

bioRxiv preprint doi: <https://doi.org/10.1101/2020.11.10.376400>; this version posted November 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under aCC0 license.

all	1.47	[0.86, 2.54]
male	1.47	[0.86, 2.54]
female	0.96	[0.30, 3.12]
current smokers	0.73	[0.34, 1.56]
never-smokers	1.35	[0.50, 3.60]

Hemorrhagic stroke

all	1.82	[0.83, 4.01]
male	1.60	[0.71, 3.61]
female	2.17	[0.47, 9.94]
current smokers	1.45	[0.41, 5.10]
never-smokers	2.34	[0.58, 9.42]

Heart failure

all	1.50	[0.97, 2.31]
male	1.76	[1.17, 2.66]
female	0.77	[0.30, 2.00]
current smokers	1.29	[0.66, 2.55]
never-smokers	1.43	[0.64, 3.21]

Atrial fibrillation

all	1.27	[0.97, 1.65]
male	1.35	[1.05, 1.73]
female	1.04	[0.57, 1.88]
current smokers	1.22	[0.72, 2.06]
never-smokers	1.20	[0.76, 1.89]

Type 2 diabetes

all	1.26	[0.97, 1.65]
male	1.31	[1.01, 1.69]
female	1.14	[0.65, 2.02]
current smokers	1.02	[0.63, 1.64]
never-smokers	1.48	[0.92, 2.38]

Any cardiovascular disease

all	1.43	[1.19, 1.72]
male	1.56	[1.31, 1.86]
female	1.07	[0.71, 1.59]
current smokers	1.27	[0.92, 1.75]
never-smokers	1.38	[1.01, 1.90]

All-cause death

all	1.41	[1.06, 1.88]
male	1.65	[1.24, 2.20]
female	0.92	[0.52, 1.63]
current smokers	1.10	[0.74, 1.63]
never-smokers	0.83	[0.51, 1.37]

Figure 2c

Observational analysis effect sizes on cardiometabolic factors

(reference = non-drinkers)

Figure S4-1

Observational analysis hazard ratio for events and odds ratio for diabetes

(reference = non-drinkers)

Figure S4-2